Cobenfy (Xanomeline/Trospium) Safety Profile and Monitoring Requirements
Contraindications
Cobenfy is absolutely contraindicated in five specific clinical scenarios that must be ruled out before prescribing. 1
- Urinary retention (active or history of) 1
- Moderate or severe hepatic impairment 1
- Gastric retention 1
- History of hypersensitivity to Cobenfy or trospium chloride 1
- Untreated narrow-angle glaucoma 1
Critical Warnings and Precautions
Urinary Retention Risk
- Cobenfy can cause acute urinary retention, with geriatric patients and those with bladder outlet obstruction at highest risk 1
- Monitor all patients for symptoms of acute urinary retention throughout treatment 1
Hepatobiliary Toxicity
- Assess liver enzymes and bilirubin before starting Cobenfy and as clinically indicated during treatment 1
- Cobenfy is not recommended in patients with mild hepatic impairment 1
- Discontinue Cobenfy immediately if signs or symptoms of substantial liver injury develop 1
Gastrointestinal Effects
- Cobenfy decreases gastrointestinal motility and must be used with caution in patients with gastrointestinal obstructive disorders due to gastric retention risk 1
- The most common adverse events include constipation, nausea, dyspepsia, vomiting, abdominal pain, diarrhea, and gastroesophageal reflux disease (all occurring in ≥5% of patients at twice the placebo rate) 1
- Constipation, nausea, dry mouth, dyspepsia, and vomiting were the most frequently reported adverse events in clinical trials 2
Cardiovascular Monitoring
- Cobenfy increases heart rate—assess heart rate at baseline and as clinically indicated during treatment 1
- Hypertension and tachycardia occur in ≥5% of patients at twice the placebo rate 1
- Supine heart rate increases were observed in clinical trials 3
Angioedema Risk
- Angioedema of the face, lips, tongue, and/or larynx has been reported with Cobenfy 1
Narrow-Angle Glaucoma
- Use Cobenfy in treated narrow-angle glaucoma only if potential benefits outweigh risks and with careful monitoring 1
Renal Impairment Considerations
Cobenfy is not recommended for patients with moderate or severe renal impairment due to expected greater anticholinergic adverse reactions from trospium accumulation 1
Central Nervous System Effects
- Cobenfy may cause CNS effects including dizziness (≥5% incidence at twice placebo rate) 1
- Advise patients not to drive or operate heavy machinery until they know how Cobenfy affects them 1
- Notably, somnolence, restlessness, and extrapyramidal symptoms occurred at similar rates to placebo 2
Metabolic and Weight Effects
Cobenfy demonstrates a favorable metabolic profile compared to traditional antipsychotics:
- Risk of ≥7% weight gain is reduced (RR=0.46, NNT=19 to prevent one case) 3
- LDL-cholesterol and HDL-cholesterol levels are reduced 3
- Triglyceride levels may increase 3
Common Adverse Events Requiring Monitoring
The following adverse events occur in ≥5% of patients at twice the placebo rate 1:
- Nausea
- Dyspepsia
- Constipation
- Vomiting
- Hypertension
- Abdominal pain
- Diarrhea
- Tachycardia
- Dizziness
- Gastroesophageal reflux disease
Tolerability Profile
- Any adverse event occurs with NNH=6 3
- Cholinergic and anticholinergic side effects are typically mild-to-moderate and mostly transient 3
- All-cause discontinuation rates are not significantly increased compared to placebo 3
- Serious adverse events and severe adverse events do not occur at higher rates than placebo 3
Drug Interactions Requiring Monitoring
- Monitor for increased Cobenfy-related adverse reactions when co-administered with strong CYP2D6 inhibitors 1
- Monitor for increased adverse reactions from drugs eliminated by active tubular secretion (competition with trospium) 1
- Monitor for increased adverse reactions from sensitive substrates of CYP3A4 or P-glycoprotein 1
- Monitor for increased anticholinergic adverse reactions when combined with other antimuscarinic drugs 1
Special Population Warnings
Geriatric Patients
- Start at 50 mg/20 mg twice daily 1
- Consider slower titration 1
- Maximum dose is 100 mg/20 mg twice daily (lower than general adult population) 1
- Increased risk of urinary retention 1
Pregnancy and Lactation
The FDA label does not provide specific pregnancy category information, but this represents a novel mechanism requiring careful risk-benefit assessment 1
Baseline and Ongoing Monitoring Algorithm
Before initiating Cobenfy:
- Liver enzymes and bilirubin 1
- Heart rate 1
- Renal function (to exclude moderate/severe impairment) 1
- Screen for contraindications (urinary retention, gastric retention, untreated narrow-angle glaucoma, hepatic impairment) 1
During treatment: